Evidence map›Paper›PMID 29450633›Full record

ArticleJournal of cancer research and clinical oncology2018

MID1-PP2A complex functions as new insights in human lung adenocarcinoma.

Lin Zhang, Junyao Li, Xuejiao Lv, Tingting Guo, Wei Li, Jie Zhang

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Advances of E3 ligases in lung cancer.Biochemistry and biophysics reports · 2024
    Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. TRIM18-Regulated STAT3 Signaling PathwayFrontiers in physiology · 2021
    Article
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Lin ZhangDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China.
Junyao LiDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China.
Xuejiao LvDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China.
Tingting GuoDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China.
Wei LiDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China.
Jie ZhangDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, 218 Ziqiang Street, Nanguan, Changchun, 130041, Jilin, People's Republic of China. doctorzhangj@sina.com.ORCID http://orcid.org/0000-0001-6795-8000
Second Affiliated Hospital of Jilin University · CN

Funding

National Natural Science Foundation of China 81472169National Natural Science Foundation of China 8167101845
6 · The paper itself

Abstract

purposeMID1 is an E3 ubiquitin ligase that was first found in Opitz G/BBB syndrome, but there has been little research into its role in lung diseases. We have found an accumulating evidence that indicates the MID1-PP2A complex plays a role in asthma and contributes to inflammation, but its roles in lung adenocarcinoma are unclear. This study aimed at evaluating the function of MID1-PP2A complex in human lung adenocarcinoma.

methodsWe used western blot, ELISA and real-time quantitative PCR to detect the protein and mRNA levels of MID1 and PP2A in A549, H1975, and H1650 lung adenocarcinoma cell lines compared with the human bronchial epithelial cell line BEAS-2B. Additionally, we used IHC, ELISA and real-time quantitative PCR to dectect MID1 and PP2A levels in 30-paired lung adenocarcinoma tissues. We also detected apoptosis, proliferation and cell cycle-related protein expression after silencing MID1 and activing PP2A.

resultsOur data show that MID1 was significantly upregulated in 30-paired lung adenocarcinoma tissues, and in A549, H1975 and H1650 cell lines compared with BEAS-2B. PP2A showed the opposite results. Furthermore, both upregulated MID1 and downregulated PP2A were correlated with age, but not sex, TNM stage or smoking history. In vitro experiments showed that PP2A was upregulated in lung adenocarcinoma cell lines that were transfected with MID1-siRNA, suggesting MID1 negatively regulates PP2A in lung adenocarcinoma. We also found that silencing MID1 expression or activating PP2A induced apoptosis, proliferation and cell cycle arrest.

conclusionsWe demonstrated that the MID1-PP2A complex plays an important role in lung adenocarcinoma, influencing cell cycle progression, proliferation and apoptosis. Our findings showed a novel molecular mechanism of lung tumorigenesis that may provide new insights for anti-tumor therapies.

Indexed as

A549 CellsAdenocarcinomaApoptosisCell Cycle CheckpointsCell LineCell Line, TumorCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansLung NeoplasmsMaleMicrotubule ProteinsMiddle AgedMultiprotein ComplexesNuclear ProteinsMicrotubule ProteinsMID1 protein, humanMultiprotein ComplexesNuclear ProteinsProtein Phosphatase 2Transcription FactorsUbiquitin-Protein LigasesApoptosisCell cycleLung adenocarcinomaMID1PP2AProliferation

Identifiers

PMID29450633
PMCPMC11813328
OpenAlexW2797459855

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.